| Year |
Citation |
Score |
| 2020 |
Cutter G, Veneziano A, Grinspan A, Al-Banna M, Boyko A, Zakharova M, Maida E, Pasic MB, Gandhi SK, Everts R, Cordioli C, Rossi S. Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD. Multiple Sclerosis and Related Disorders. 40: 101957. PMID 32028117 DOI: 10.1016/J.Msard.2020.101957 |
0.343 |
|
| 2020 |
Salter A, Fox RJ, Tyry T, Cutter G, Marrie RA. New applications for independent activities of daily living in measuring disability in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458519898591. PMID 31933419 DOI: 10.1177/1352458519898591 |
0.343 |
|
| 2019 |
Koch MW, Mostert J, Uitdehaag B, Cutter G. Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458519876701. PMID 31517591 DOI: 10.1177/1352458519876701 |
0.347 |
|
| 2019 |
Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, Goldberg JD, Li X, Riddle E, Smirnakis K, Kasliwal R, Ren Z, Hotermans C, Ho PR, Campbell N. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. PMID 31515290 DOI: 10.1212/Wnl.0000000000008243 |
0.341 |
|
| 2019 |
Manouchehri N, Zhang Y, Salter A, Hussain RZ, Hartung HP, Hemmer B, Linker R, Segal BM, Cutter G, Stüve O. Clinical trials in multiple sclerosis: potential future trial designs. Therapeutic Advances in Neurological Disorders. 12: 1756286419847095. PMID 31205492 DOI: 10.1177/1756286419847095 |
0.405 |
|
| 2019 |
Cutter G, Veneziano A, Grinspan A, Al-Banna M, Boyko A, Zakharova M, Maida E, Pasic MB, Gandhi SK, Everts R, Cordioli C, Rossi S. Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS. Multiple Sclerosis and Related Disorders. 33: 13-21. PMID 31132664 DOI: 10.1016/J.Msard.2019.04.036 |
0.335 |
|
| 2019 |
Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Marrie RA. Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458519845836. PMID 31079537 DOI: 10.1177/1352458519845836 |
0.342 |
|
| 2019 |
Salter A, Fox RJ, Tyry T, Cutter G, Marrie RA. The association of fatigue and social participation in multiple sclerosis as assessed using two different instruments. Multiple Sclerosis and Related Disorders. 31: 165-172. PMID 31063935 DOI: 10.1016/J.Msard.2019.04.014 |
0.344 |
|
| 2019 |
Baird JF, Sasaki JE, Sandroff BM, Cutter G, Motl RW. An Intervention for Changing Sedentary Behavior Among African Americans With Multiple Sclerosis: Protocol. Jmir Research Protocols. 8: e12973. PMID 31042149 DOI: 10.2196/12973 |
0.341 |
|
| 2019 |
Motl RW, Backus D, Neal WN, Cutter G, Palmer L, McBurney R, Schmidt H, Bethoux F, Hebert J, Ng A, McCully K, Plummer P. Rationale and design of the STEP for MS Trial: Comparative effectiveness of Supervised versus Telerehabilitation Exercise Programs for Multiple Sclerosis. Contemporary Clinical Trials. PMID 31022481 DOI: 10.1016/J.Cct.2019.04.013 |
0.336 |
|
| 2019 |
Kannan M, Hildebrand A, Hugos CL, Chahine R, Cutter G, Cameron MH. Evaluation of a web-based fall prevention program among people with multiple sclerosis. Multiple Sclerosis and Related Disorders. 31: 151-156. PMID 31004969 DOI: 10.1016/J.Msard.2019.04.015 |
0.317 |
|
| 2019 |
Pardini M, Cutter G, Sormani MP. Multiple sclerosis: clinical trial design 2019. Current Opinion in Neurology. PMID 30950845 DOI: 10.1097/Wco.0000000000000697 |
0.39 |
|
| 2019 |
Zhang Y, Salter A, Wallström E, Cutter G, Stüve O. Evolution of clinical trials in multiple sclerosis. Therapeutic Advances in Neurological Disorders. 12: 1756286419826547. PMID 30833985 DOI: 10.1177/1756286419826547 |
0.397 |
|
| 2019 |
Nelson LM, Wallin MT, Marrie RA, Culpepper WJ, Langer-Gould A, Campbell J, Buka S, Tremlett H, Cutter G, Kaye W, Wagner L, Larocca NG. A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS. Neurology. PMID 30770422 DOI: 10.1212/Wnl.0000000000007044 |
0.338 |
|
| 2019 |
Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, ... ... Cutter GR, et al. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. The Lancet. Neurology. PMID 30692052 DOI: 10.1016/S1474-4422(18)30392-2 |
0.324 |
|
| 2019 |
Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Mowry EM, Marrie RA. Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes. Multiple Sclerosis and Related Disorders. 29: 86-93. PMID 30690340 DOI: 10.1016/J.Msard.2019.01.031 |
0.342 |
|
| 2019 |
Shih C, Blakeley J, Clapp DW, Armstrong AE, Wolters P, Dombi E, Cutter G, Ullrich NJ, Allen J, Packer R, Goldman S, Gutmann DH, Plotkin S, Rosser T, Robertson K, et al. Abstract CT233: Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium Phase II trial Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct233 |
0.315 |
|
| 2018 |
Zhang Y, Salter A, Cutter G, Stϋve O. Clinical trials in multiple sclerosis: milestones. Therapeutic Advances in Neurological Disorders. 11: 1756286418785499. PMID 30034537 DOI: 10.1177/1756286418785499 |
0.401 |
|
| 2018 |
Goodin DS, Reder AT, Traboulsee AL, Li DK, Langdon D, Cutter G, Cook S, O'Donnell T, Kremenchutzky M, Oger J, Koelbach R, Pohl C, Wicklein EM. Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458518773511. PMID 29761737 DOI: 10.1177/1352458518773511 |
0.316 |
|
| 2018 |
Fitzgerald KC, Tyry T, Salter A, Cofield SS, Cutter G, Fox RJ, Marrie RA. A survey of dietary characteristics in a large population of people with multiple sclerosis. Multiple Sclerosis and Related Disorders. 22: 12-18. PMID 29510324 DOI: 10.1016/J.Msard.2018.02.019 |
0.326 |
|
| 2018 |
Sasaki JE, Motl RW, Cutter G, Marrie RA, Tyry T, Salter A. Factors associated with excessive sitting time in multiple sclerosis. Multiple Sclerosis and Related Disorders. 21: 71-77. PMID 29477021 DOI: 10.1016/J.Msard.2018.02.009 |
0.344 |
|
| 2018 |
Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger R, Goldberg JD, Li X, Riddle E, Smirnakis K, Yu B, Ren Z, Hotermans C, Ho P, Campbell N. 071 Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch® prescribing program Journal of Neurology, Neurosurgery & Psychiatry. 89: A29.2-A29. DOI: 10.1136/Jnnp-2018-Anzan.70 |
0.309 |
|
| 2017 |
Fitzgerald KC, Tyry T, Salter A, Cofield SS, Cutter G, Fox R, Marrie RA. Diet quality is associated with disability and symptom severity in multiple sclerosis. Neurology. PMID 29212827 DOI: 10.1212/Wnl.0000000000004768 |
0.304 |
|
| 2017 |
Benatar M, Howard JF, Barohn R, Wolfe GI, Cutter G. Learning from the past: reflections on recently completed myasthenia gravis trials. Annals of the New York Academy of Sciences. PMID 29064567 DOI: 10.1111/Nyas.13501 |
0.349 |
|
| 2017 |
Pardini M, Cutter G, Sormani MP. Clinical trial design for progressive MS trials. Multiple Sclerosis (Houndmills, Basingstoke, England). 23: 1642-1648. PMID 29041873 DOI: 10.1177/1352458517729461 |
0.347 |
|
| 2017 |
Chan A, Cutter G, Fox RJ, Xiao J, Lewin JB, Edwards MR. Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research. PMID 28350241 DOI: 10.2217/Cer-2016-0085 |
0.327 |
|
| 2017 |
Giovannoni G, Cutter G, Pia-Sormani M, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D, Leppert D, Herndon R, Wheeler-Kingshott CA, Ciccarelli O, Selwood D, di Cantogno EV, Ben-Amor AF, et al. Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Multiple Sclerosis and Related Disorders. 12: 70-78. PMID 28283111 DOI: 10.1016/J.Msard.2017.01.007 |
0.372 |
|
| 2017 |
Newsome SD, Aliotta PJ, Bainbridge J, Bennett SE, Cutter G, Fenton K, Lublin F, Northrop D, Rintell D, Walker BD, Weigel M, Zackowski K, Jones DE. A Framework of Care in Multiple Sclerosis, Part 2: Symptomatic Care and Beyond. International Journal of Ms Care. 19: 42-56. PMID 28243186 DOI: 10.7224/1537-2073.2016-062 |
0.358 |
|
| 2016 |
Salter A, Thomas N, Tyry T, Cutter G, Marrie RA. Employment and absenteeism in working-age persons with multiple sclerosis. Journal of Medical Economics. 1-24. PMID 28035846 DOI: 10.1080/13696998.2016.1277229 |
0.353 |
|
| 2016 |
Hunter SF, Agius M, Miller DM, Cutter G, Barbato L, McCague K, Meng X, Agashivala N, Chin P, Hollander E. Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial. Journal of the Neurological Sciences. 365: 190-8. PMID 27206905 DOI: 10.1016/J.Jns.2016.03.024 |
0.366 |
|
| 2016 |
Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, Smith D, Kolb C, Qureshi S, Okuda D, Kalina J, ... ... Cutter G, et al. Extended interval dosing of natalizumab in multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 26917698 DOI: 10.1136/Jnnp-2015-312940 |
0.328 |
|
| 2015 |
Capkun G, Dahlke F, Lahoz R, Nordstrom B, Tilson HH, Cutter G, Bischof D, Moore A, Simeone J, Fraeman K, Bancken F, Geissbühler Y, Wagner M, Cohan S. Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database. Multiple Sclerosis and Related Disorders. 4: 546-54. PMID 26590661 DOI: 10.1016/J.Msard.2015.08.005 |
0.359 |
|
| 2015 |
Fox RJ, Cutter G, Chan A, Xiao J, Okwuokenye M, Levison D, Lewin J, Edwards MR, Marantz JL. Comparative Effectiveness Using A Matching-Adjusted Indirect Comparison Between Delayed-Release Dimethyl Fumarate and Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 18: A750. PMID 26534203 DOI: 10.1016/J.Jval.2015.09.2902 |
0.309 |
|
| 2015 |
Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, et al. Defining reliable disability outcomes in multiple sclerosis. Brain : a Journal of Neurology. 138: 3287-98. PMID 26359291 DOI: 10.1093/Brain/Awv258 |
0.363 |
|
| 2015 |
Culpepper WJ, Wallin MT, Magder LS, Perencevich E, Royal W, Bradham DD, Cutter G, Bever CT. VHA Multiple Sclerosis Surveillance Registry and its similarities to other contemporary multiple sclerosis cohorts. Journal of Rehabilitation Research and Development. 52: 263-72. PMID 26220064 DOI: 10.1682/Jrrd.2014.07.0172 |
0.377 |
|
| 2015 |
Fox RJ, Salter A, Alster JM, Dawson NV, Kattan MW, Miller D, Ramesh S, Tyry T, Wells BW, Cutter G. Risk tolerance to MS therapies: Survey results from the NARCOMS registry. Multiple Sclerosis and Related Disorders. 4: 241-9. PMID 26008941 DOI: 10.1016/J.Msard.2015.03.003 |
0.372 |
|
| 2015 |
Koch MW, Korngut L, Patry DG, Agha-Khani Y, White C, Sarna JR, Yeung M, Yong VW, Heng DY, Cutter G, Metz L. The promise of futility trials in neurological diseases. Nature Reviews. Neurology. 11: 300-5. PMID 25776824 DOI: 10.1038/Nrneurol.2015.34 |
0.343 |
|
| 2015 |
Marrie RA, Cohen J, Stuve O, Trojano M, Sørensen PS, Reingold S, Cutter G, Reider N. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 263-81. PMID 25623244 DOI: 10.1177/1352458514564491 |
0.321 |
|
| 2015 |
Marrie RA, Reingold S, Cohen J, Stuve O, Trojano M, Sorensen PS, Cutter G, Reider N. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 305-17. PMID 25583845 DOI: 10.1177/1352458514564487 |
0.308 |
|
| 2015 |
Meng X, Chin PS, Hashmonay R, Zahur Islam M, Cutter G. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Contemporary Clinical Trials. 41: 69-74. PMID 25545026 DOI: 10.1016/J.Cct.2014.12.011 |
0.316 |
|
| 2015 |
Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Sorensen PS, Reingold SC, Cutter G. A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 294-304. PMID 25533302 DOI: 10.1177/1352458514564489 |
0.302 |
|
| 2015 |
Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, Reingold S, Sorensen PS. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 318-31. PMID 25533300 DOI: 10.1177/1352458514564485 |
0.333 |
|
| 2015 |
Marrie RA, Reider N, Cohen J, Stuve O, Sorensen PS, Cutter G, Reingold SC, Trojano M. A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 282-93. PMID 25533299 DOI: 10.1177/1352458514564490 |
0.337 |
|
| 2014 |
Lublin FD, Cutter G, Giovannoni G, Pace A, Campbell NR, Belachew S. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. Multiple Sclerosis and Related Disorders. 3: 705-11. PMID 25891549 DOI: 10.1016/J.Msard.2014.08.005 |
0.361 |
|
| 2014 |
Kaufman DW, Reshef S, Golub HL, Peucker M, Corwin MJ, Goodin DS, Knappertz V, Pleimes D, Cutter G. Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S. Multiple Sclerosis and Related Disorders. 3: 364-71. PMID 25876474 DOI: 10.1016/J.Msard.2013.12.003 |
0.345 |
|
| 2014 |
Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Advances in Therapy. 31: 1134-54. PMID 25414048 DOI: 10.1007/S12325-014-0167-Z |
0.329 |
|
| 2014 |
Goodin DS, Corwin M, Kaufman D, Golub H, Reshef S, Rametta MJ, Knappertz V, Cutter G, Pleimes D. Causes of death among commercially insured multiple sclerosis patients in the United States. Plos One. 9: e105207. PMID 25144226 DOI: 10.1371/Journal.Pone.0105207 |
0.349 |
|
| 2014 |
Zhang J, Waubant E, Cutter G, Wolinsky J, Leppert D. Composite end points to assess delay of disability progression by MS treatments. Multiple Sclerosis Journal. 20: 1494-1501. PMID 24675040 DOI: 10.1177/1352458514527180 |
0.335 |
|
| 2014 |
Cutter G, Kappos L. Clinical trials in multiple sclerosis. Handbook of Clinical Neurology. 122: 445-53. PMID 24507530 DOI: 10.1016/B978-0-444-52001-2.00019-4 |
0.308 |
|
| 2014 |
Schneider LS, Kennedy RE, Wang G, Cutter G. P4-176: DIFFERENCES IN ALZHEIMER DISEASE CLINICAL TRIALS OUTCOMES BASED ON AGE OF PATIENTS Alzheimer's & Dementia. 10: P853-P853. DOI: 10.1016/J.Jalz.2014.05.1693 |
0.32 |
|
| 2013 |
Koch MW, Cutter G, Stys PK, Yong VW, Metz LM. Treatment trials in progressive MS--current challenges and future directions. Nature Reviews. Neurology. 9: 496-503. PMID 23897406 DOI: 10.1038/Nrneurol.2013.148 |
0.403 |
|
| 2013 |
Scalfari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC. Mortality in patients with multiple sclerosis. Neurology. 81: 184-92. PMID 23836941 DOI: 10.1212/Wnl.0B013E31829A3388 |
0.384 |
|
| 2013 |
Zhang J, Waubant E, Cutter G, Wolinsky JS, Glanzman R. EDSS variability before randomization may limit treatment discovery in primary progressive MS. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 775-81. PMID 23027880 DOI: 10.1177/1352458512459685 |
0.366 |
|
| 2013 |
Rossi S, Motta C, Studer V, De Chiara V, Barbieri F, Monteleone F, Fornasiero A, Coarelli G, Bernardi G, Cutter G, Stüve O, Salvetti M, Centonze D. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 20: 87-94. PMID 22741530 DOI: 10.1111/J.1468-1331.2012.03794.X |
0.358 |
|
| 2013 |
Rossi S, Motta C, Studer V, Monteleone F, De Chiara V, Buttari F, Barbieri F, Bernardi G, Battistini L, Cutter G, Stüve O, Salvetti M, Centonze D. A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 59-68. PMID 22577119 DOI: 10.1177/1352458512448106 |
0.333 |
|
| 2012 |
Goodin DS, Ebers GC, Cutter G, Cook SD, O'Donnell T, Reder AT, Kremenchutzky M, Oger J, Rametta M, Beckmann K, Knappertz V. Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study. Bmj Open. 2. PMID 23204140 DOI: 10.1136/Bmjopen-2012-001972 |
0.36 |
|
| 2012 |
Goodin DS, Reder AT, Cutter G. Treatment with interferon beta for multiple sclerosis. Jama. 308: 1627; author reply 1. PMID 23093155 DOI: 10.1001/Jama.2012.13570 |
0.331 |
|
| 2012 |
Pan F, Goh JW, Cutter G, Su W, Pleimes D, Wang C. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States. Clinical Therapeutics. 34: 1966-76. PMID 22906738 DOI: 10.1016/J.Clinthera.2012.07.010 |
0.369 |
|
| 2012 |
Zivadinov R, Cutter G, Marr K, Ramanathan M, Benedict RH, Bergsland N, Morgan C, Carl E, Hojnacki D, Yeh EA, Willis L, Cherneva M, Kennedy C, Dwyer MG, Weinstock-Guttman B. No association between conventional brain MR imaging and chronic cerebrospinal venous insufficiency in multiple sclerosis. Ajnr. American Journal of Neuroradiology. 33: 1913-7. PMID 22576891 DOI: 10.3174/Ajnr.A3112 |
0.332 |
|
| 2012 |
Kister I, Chamot E, Cutter G, Bacon TE, Jokubaitis VG, Hughes SE, Gray OM, Trojano M, Izquierdo G, Grand'Maison F, Duquette P, Lugaresi A, Grammond P, Boz C, Hupperts R, et al. Increasing age at disability milestones among MS patients in the MSBase Registry. Journal of the Neurological Sciences. 318: 94-9. PMID 22507751 DOI: 10.1016/J.Jns.2012.03.017 |
0.349 |
|
| 2012 |
Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology. 78: 1315-22. PMID 22496198 DOI: 10.1212/Wnl.0B013E3182535Cf6 |
0.349 |
|
| 2012 |
Papadopoulou A, von Felten S, Traud S, Rahman A, Quan J, King R, Garren H, Steinman L, Cutter G, Kappos L, Radue EW. Evolution of MS lesions to black holes under DNA vaccine treatment. Journal of Neurology. 259: 1375-82. PMID 22222856 DOI: 10.1007/S00415-011-6361-X |
0.34 |
|
| 2012 |
Minisman G, Bhanushali M, Conwit R, Wolfe GI, Aban I, Kaminski HJ, Cutter G. Implementing clinical trials on an international platform: Challenges and perspectives Journal of the Neurological Sciences. 313: 1-6. PMID 22047648 DOI: 10.1016/J.Jns.2011.10.004 |
0.329 |
|
| 2012 |
Marrie RA, Horwitz R, Cutter G, Tyry T. Cumulative impact of comorbidity on quality of life in MS Acta Neurologica Scandinavica. 125: 180-186. PMID 21615355 DOI: 10.1111/J.1600-0404.2011.01526.X |
0.322 |
|
| 2012 |
Wolinsky J, Narayana P, Nelson F, Datta S, Cofield S, Cutter G, Conwit R, Gustafson T, Lublin F. The CombiRx Trial: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Participants with Relapsing-Remitting Multiple Sclerosis – Clinical Outcomes (PL02.003) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.Pl02.003 |
0.378 |
|
| 2012 |
Marrie R, Cutter G, Tyry T. High Frequency and Adverse Impact of Vertigo and Dizziness in Multiple Sclerosis (P07.075) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P07.075 |
0.368 |
|
| 2012 |
Kister I, Chamot E, Salter A, Cutter G, Bacon T, Kalina J, Herbert J. Natural History of MS Symptoms: Perceived Disease Impact across Disease Span in Nine Neurologic Domains among Enrollees in North American Research Committee on Multiple Sclerosis (NARCOMS) Registry (P07.073) Neurology. 78: P07.073-P07.073. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P07.073 |
0.328 |
|
| 2012 |
Reshef S, Cutter G, Golub H, Brueckner A, Knappertz V. Mortality in Multiple Sclerosis in the United States (MIMS-US): A Retrospective, Cohort Study of Survival and Mortality Trends (P06.195) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P06.195 |
0.373 |
|
| 2012 |
Fox R, Hornung L, Cofield S, Cutter G. Relationship between Symptom Worsening, Relapse Activity and Disease Progression in Patients with Multiple Sclerosis (P05.094) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P05.094 |
0.312 |
|
| 2012 |
Reder A, Goodin D, Ebers G, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, Knappertz V. Clinical Outcomes and Cause of Death for Interferon Beta-1b Versus Placebo, 21 Years Following Randomization (P04.129) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P04.129 |
0.397 |
|
| 2012 |
Zhang J, Waubant E, Cutter G, Wolinsky J, Glanzman R. Improvements in the Power of Detecting Treatment Effect in a Primary Progressive Multiple Sclerosis (PPMS) Clinical Trial with the Use of Composite Disability Outcome Endpoints (P01.151) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P01.151 |
0.341 |
|
| 2012 |
Kazamel M, Cutter G, King P. Amyotrophic Lateral Sclerosis in a Large African American Population, Does It Differ from Caucasians? (P01.098) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P01.098 |
0.302 |
|
| 2012 |
You Z, Williams OD, Aban I, Kabagambe EK, Tiwari HK, Cutter G. Response to the Letter 'Efficiency loss due to varying cluster sizes in cluster randomized trials and how to compensate for it: Comment on You et al. (2011)' by van Breukelen and Candel Clinical Trials. 9: 126-127. DOI: 10.1177/1740774511429832 |
0.479 |
|
| 2011 |
Motl RW, Fernhall B, McAuley E, Cutter G. Physical activity and self-reported cardiovascular comorbidities in persons with multiple sclerosis: evidence from a cross-sectional analysis. Neuroepidemiology. 36: 183-91. PMID 21597305 DOI: 10.1159/000327749 |
0.308 |
|
| 2011 |
Zivadinov R, Marr K, Cutter G, Ramanathan M, Benedict RH, Kennedy C, Elfadil M, Yeh AE, Reuther J, Brooks C, Hunt K, Andrews M, Carl E, Dwyer MG, Hojnacki D, et al. Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology. 77: 138-44. PMID 21490322 DOI: 10.1212/Wnl.0B013E318212A901 |
0.356 |
|
| 2011 |
Weinstock-Guttman B, Zivadinov R, Cutter G, Tamaño-Blanco M, Marr K, Badgett D, Carl E, Elfadil M, Kennedy C, Benedict RH, Ramanathan M. Chronic cerebrospinal vascular insufficiency is not associated with HLA DRB1*1501 status in multiple sclerosis patients. Plos One. 6: e16802. PMID 21340025 DOI: 10.1371/Journal.Pone.0016802 |
0.354 |
|
| 2011 |
Marrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T. Smokers with multiple sclerosis are more likely to report comorbid autoimmune diseases Neuroepidemiology. 36: 85-90. PMID 21282965 DOI: 10.1159/000323948 |
0.309 |
|
| 2011 |
Kister I, Chamot E, Bacon JH, Cutter G, Herbert J. Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium. Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 725-33. PMID 21270059 DOI: 10.1177/1352458510396269 |
0.35 |
|
| 2011 |
You Z, Williams OD, Aban I, Kabagambe EK, Tiwari HK, Cutter G. Relative efficiency and sample size for cluster randomized trials with variable cluster sizes. Clinical Trials (London, England). 8: 27-36. PMID 21163852 DOI: 10.1177/1740774510391492 |
0.478 |
|
| 2011 |
Marrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T. Association between comorbidity and clinical characteristics of MS Acta Neurologica Scandinavica. 124: 135-141. PMID 20880264 DOI: 10.1111/J.1600-0404.2010.01436.X |
0.362 |
|
| 2011 |
Ernst FR, Preblick R, Cutter G, Kaufman DW, Golub H, Pocoski J, Knappertz V. Proportion of in-hospital deaths in multiple sclerosis patients related to septicaemia and upper respiratory infection exceeds that in non-multiple sclerosis patients F1000research. 2. DOI: 10.7490/F1000Research.1632.1 |
0.308 |
|
| 2011 |
Reshef S, Cutter G, Kaufman DW, Golub H, Preblick R, Bruckner A, Knappertz V. Mortality and survival trends in US multiple sclerosis patients F1000research. 2. DOI: 10.7490/F1000Research.1617.1 |
0.301 |
|
| 2010 |
Frohman EM, Cutter G, Remington G, Gao H, Rossman H, Weinstock-Guttman B, Durfee JE, Conger A, Carl E, Treadaway K, Lindzen E, Salter A, Frohman TC, Shah A, Bates A, et al. A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders. 3: 15-28. PMID 21180633 DOI: 10.1177/1756285609353354 |
0.351 |
|
| 2010 |
Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, Gold R, Hartung HP, Lublin F, Miravalle A, Montalban X, O'Connor P, Olsson T, Polman CH, Stuve O, et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Annals of Neurology. 68: 409-11. PMID 20818795 DOI: 10.1002/Ana.22083 |
0.322 |
|
| 2010 |
Poonawalla AH, Datta S, Juneja V, Nelson F, Wolinsky JS, Cutter G, Narayana PA. Composite MRI scores improve correlation with EDSS in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 1117-25. PMID 20813778 DOI: 10.1177/1352458510374892 |
0.316 |
|
| 2010 |
Syc SB, Warner CV, Hiremath GS, Farrell SK, Ratchford JN, Conger A, Frohman T, Cutter G, Balcer LJ, Frohman EM, Calabresi PA. Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 829-39. PMID 20530512 DOI: 10.1177/1352458510371640 |
0.331 |
|
| 2010 |
Healy BC, Ikle D, Macklin EA, Cutter G. Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint: Multiple Sclerosis Journal. 16: 840-847. PMID 20530124 DOI: 10.1177/1352458510371409 |
0.318 |
|
| 2010 |
Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis Neurology. 74: 1041-1047. PMID 20350978 DOI: 10.1212/Wnl.0B013E3181D6B125 |
0.353 |
|
| 2010 |
Mark V, Taub E, Bashir K, Uswatte G, Bryson C, McKay S, Cutter G. 292 CONSTRAINT-INDUCED MOVEMENT THERAPY FOR IMPAIRED GAIT IN PROGRESSIVE MS: 1-YEAR FOLLOW-UP Parkinsonism & Related Disorders. 16: S83. DOI: 10.1016/S1353-8020(10)70293-5 |
0.304 |
|
| 2009 |
Marrie RA, Cutter G. Editorial: Relapses in multiple sclerosis: Important or not? Neurology. 73: 1612-1613. PMID 19890072 DOI: 10.1212/Wnl.0B013E3181C17Fb5 |
0.399 |
|
| 2009 |
Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, Jeffery D, Cohen B, Mankowski K, Guarnaccia J, Schaeffer L, Kanter R, Brandes D, Kaufman C, Duncan D, et al. Factors that influence adherence with disease-modifying therapy in MS. Journal of Neurology. 256: 568-76. PMID 19444532 DOI: 10.1007/S00415-009-0096-Y |
0.335 |
|
| 2009 |
Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS Neurology. 72: 117-124. PMID 18971448 DOI: 10.1212/01.Wnl.0000333252.78173.5F |
0.32 |
|
| 2009 |
Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. High frequency of adverse health behaviors in multiple sclerosis Multiple Sclerosis. 15: 105-113. PMID 18845651 DOI: 10.1177/1352458508096680 |
0.307 |
|
| 2009 |
Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Differences in Bladder Care for Veterans with Multiple Sclerosis by Treatment Location International Journal of Ms Care. 11: 91-97. DOI: 10.7224/1537-2073-11.2.91 |
0.322 |
|
| 2008 |
Cettomai D, Pulicken M, Gordon-Lipkin E, Salter A, Frohman TC, Conger A, Zhang X, Cutter G, Balcer LJ, Frohman EM, Calabresi PA. Reproducibility of optical coherence tomography in multiple sclerosis. Archives of Neurology. 65: 1218-22. PMID 18779426 DOI: 10.1001/Archneur.65.9.1218 |
0.364 |
|
| 2008 |
Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status and multiple sclerosis Multiple Sclerosis. 14: 1091-1098. PMID 18728060 DOI: 10.1177/1352458508092263 |
0.374 |
|
| 2008 |
Zhang X, Cutter G. Bayesian interim analysis in clinical trials. Contemporary Clinical Trials. 29: 751-755. PMID 18589003 DOI: 10.1016/J.Cct.2008.05.007 |
0.313 |
|
| 2008 |
Mark VW, Taub E, Bashir K, Uswatte G, Delgado A, Bowman MH, Bryson CC, McKay S, Cutter GR. Constraint-Induced Movement therapy can improve hemiparetic progressive multiple sclerosis. Preliminary findings. Multiple Sclerosis (Houndmills, Basingstoke, England). 14: 992-4. PMID 18573826 DOI: 10.1177/1352458508090223 |
0.345 |
|
| 2008 |
Newsom-Davis J, Cutter G, Wolfe GI, Kaminski HJ, Jaretzki A, Minisman G, Aban I, Conwit R. Status of the Thymectomy Trial for Nonthymomatous Myasthenia Gravis Patients Receiving Prednisone Annals of the New York Academy of Sciences. 1132: 344-347. PMID 18567886 DOI: 10.1196/Annals.1405.014 |
0.308 |
|
| 2008 |
Cutter G, Aban I. Rules of evidence for clinical trials: the science of finding the truth? Annals of the New York Academy of Sciences. 1132: 233-7. PMID 18567873 DOI: 10.1196/Annals.1405.025 |
0.323 |
|
| 2007 |
Pulicken M, Gordon-Lipkin E, Balcer LJ, Frohman E, Cutter G, Calabresi PA. Optical coherence tomography and disease subtype in multiple sclerosis. Neurology. 69: 2085-92. PMID 18040015 DOI: 10.1212/01.Wnl.0000294876.49861.Dc |
0.325 |
|
| 2007 |
Gordon-Lipkin E, Chodkowski B, Reich DS, Smith SA, Pulicken M, Balcer LJ, Frohman EM, Cutter G, Calabresi PA. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology. 69: 1603-9. PMID 17938370 DOI: 10.1212/01.Wnl.0000295995.46586.Ae |
0.338 |
|
| 2007 |
Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Disparities in the management of multiple sclerosis-related bladder symptoms Neurology. 68: 1971-1978. PMID 17548546 DOI: 10.1212/01.Wnl.0000264416.53077.8B |
0.337 |
|
| 2007 |
Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Validation of the NARCOMS registry: Diagnosis Multiple Sclerosis. 13: 770-775. PMID 17525097 DOI: 10.1177/1352458506075031 |
0.324 |
|
| 2007 |
Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo L, Kadosh S, Ladkani D, Kastrukoff L, Duquette P, Freedman M, Debouverie M, Lubetski C, ... ... Cutter G, et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial Annals of Neurology. 61: 14-24. PMID 17262850 DOI: 10.1002/Ana.21079 |
0.349 |
|
| 2006 |
Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races? Neurology. 66: 1235-1240. PMID 16636241 DOI: 10.1212/01.Wnl.0000208505.81912.82 |
0.346 |
|
| 2006 |
Miller DM, Cohen JA, Kooijmans M, Tsao E, Cutter G, Baier M. Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study. Multiple Sclerosis (Houndmills, Basingstoke, England). 12: 180-6. PMID 16629421 DOI: 10.1191/135248506Ms1270Oa |
0.351 |
|
| 2006 |
Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Archives of Neurology. 63: 614-9. PMID 16606781 DOI: 10.1001/Archneur.63.4.614 |
0.34 |
|
| 2005 |
Bielekova B, Kadom N, Fisher E, Jeffries N, Ohayon J, Richert N, Howard T, Bash CN, Frank JA, Stone L, Martin R, Cutter G, McFarland HF. MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology. 65: 1071-6. PMID 16217061 DOI: 10.1212/01.Wnl.0000178984.30534.F9 |
0.356 |
|
| 2005 |
Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T. Changes in the ascertainment of multiple sclerosis Neurology. 65: 1066-1070. PMID 16217060 DOI: 10.1212/01.Wnl.0000178891.20579.64 |
0.373 |
|
| 2005 |
Schiffer RB, Arnett P, Ben-Zacharia A, Benedict R, Bobholz J, Caruso L, Chelune G, Cox D, Cutter G, DiLorenzo T, DeLuca J, Epstein J, Feinstein A, Ferrando SJ, Fischer J, et al. The Goldman Consensus statement on depression in multiple sclerosis Multiple Sclerosis. 11: 328-337. PMID 15957516 DOI: 10.1191/1352458505Ms1162Oa |
0.341 |
|
| 2005 |
Kaufman M, Cutter G, Schwid S, Johnson K, Halper J, Birnbaum G, Ellerbe M, Foley F, Herndon R, Lublin F, Rammohan K, Rossman H, Stell L. Longitudinal Assessment of Multiple Sclerosis Patients and Reimbursement Issues International Journal of Ms Care. 7: 129-131. DOI: 10.7224/1537-2073-7.4.129 |
0.353 |
|
| 2004 |
Cohen J, Cutter G, Lublin F, Schwid S. The MS Co-O perative Research (MS-CORE) group: an alternate approach to fostering multicenter studies Multiple Sclerosis Journal. 10: 332-335. PMID 15222702 DOI: 10.1191/1352458504Ms1018Xx |
0.315 |
|
| 2003 |
Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis Neurology. 61: 1528-1532. PMID 14663037 DOI: 10.1212/01.Wnl.0000096175.39831.21 |
0.394 |
|
| 2003 |
Cutter G. Statistical issues in neutralizing antibodies Neurology. 61. PMID 14610112 DOI: 10.1212/01.Wnl.0000092365.14383.56 |
0.307 |
|
| 2003 |
Scott TF, Schramke CJ, Cutter G. Sample size estimates for determining treatment effects in high-risk patients with early relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. 9: 289-292. PMID 12814177 DOI: 10.1191/1352458503Ms910Oa |
0.34 |
|
| 2003 |
Miller DM, Rudick RA, Baier M, Cutter G, Doughtery DS, Weinstock-Guttman B, Mass MK, Fisher E, Simonian N. Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 9: 1-5. PMID 12617260 DOI: 10.1191/1352458503Ms888Oa |
0.341 |
|
| 2002 |
Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee JC, Miller D, Weinstock-Guttman B, Mass MK, Dougherty DS, Simonian NA. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 59: 1412-20. PMID 12427893 DOI: 10.1212/01.Wnl.0000036271.49066.06 |
0.347 |
|
| 2002 |
Rudick RA, Cutter G, Reingold S. The Multiple Sclerosis Functional Composite: A new clinical outcome measure for multiple sclerosis trials Multiple Sclerosis. 8: 359-365. PMID 12356200 DOI: 10.1191/1352458502Ms845Oa |
0.399 |
|
| 2001 |
Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, Mass MK, Miller D, Simonian NA. Use of the multiple sclerosis functional composite to predict disability in relapsing MS Neurology. 56: 1324-1330. PMID 11376182 DOI: 10.1212/Wnl.56.10.1324 |
0.408 |
|
| 2000 |
Fisher E, Rudick RA, Cutter G, Baier M, Miller D, Weinstock-Guttman B, Mass MK, Dougherty DS, Simonian NA. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Multiple Sclerosis (Houndmills, Basingstoke, England). 6: 373-7. PMID 11212131 DOI: 10.1177/135245850000600602 |
0.381 |
|
| 2000 |
Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Archives of Neurology. 57: 1319-24. PMID 10987899 DOI: 10.1001/Archneur.57.9.1319 |
0.338 |
|
| 1997 |
Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, et al. Recommendations from the national multiple sclerosis society clinical outcomes assessment task force Annals of Neurology. 42: 379-382. PMID 9307263 DOI: 10.1002/Ana.410420318 |
0.374 |
|
| 1996 |
Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, et al. Clinical outcomes assessment in multiple sclerosis Annals of Neurology. 40: 469-479. PMID 8797541 DOI: 10.1002/Ana.410400321 |
0.319 |
|
| Show low-probability matches. |